FDA Approves ANDA for Tofacitinib Citrate by Auson
The FDA has approved the ANDA219370 for Tofacitinib Citrate submitted by Auson.
Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Immunology / JAK Inhibitor
Asset: Auson
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Auson
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Auson's ANDA for Tofacitinib Citrate introduces a generic competitor into the immunology market, which could disrupt pricing and market dynamics. Existing branded therapies will need to adapt their strategies to maintain market share in light of increased competition.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of Auson, as well as responses from competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.